EP Patent

EP3210975A1 — Cocrystals of lorcaserin

Assigned to Enantia SL · Expires 2017-08-30 · 9y expired

What this patent protects

Cocrystals of Lorcaserin hydrochloride and an organic diacid, in particular with (+)-di-p-toluoyl-D-tartaric acid; (+)-camphoric acid; and oxalic acid, processes for their preparation, their therapeutical indications, as well as, pharmaceutical compositions containing the…

USPTO Abstract

Cocrystals of Lorcaserin hydrochloride and an organic diacid, in particular with (+)-di-p-toluoyl-D-tartaric acid; (+)-camphoric acid; and oxalic acid, processes for their preparation, their therapeutical indications, as well as, pharmaceutical compositions containing them. It also relates to a resolution process of lorcaserin which goes through the formation of the cocrystal of (R)-Lorcaserin hydrochloride with (+)-di-p-toluoyl-D-tartaric.

Drugs covered by this patent

Patent Metadata

Patent number
EP3210975A1
Jurisdiction
EP
Classification
—
Expires
2017-08-30
Drug substance claim
No
Drug product claim
No
Assignee
Enantia SL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.